| Epidemiology | Lifetime | 274 | US 140 | 99.66 |
| Clinical Pharmacology | Lifetime | 198 | US 87 | 99.19 |
| Molecular Medicine | Lifetime | 84 | US 29 | 98.15 |
| Clinical Biochemistry | Lifetime | 128 | US 64 | 97.70 |
| Management, Monitoring, Policy and Law | Lifetime | 810 | US 226 | 96.99 |
| Infectious Diseases | Lifetime | 631 | US 328 | 97.39 |
| Financial Markets, Risk and Investment | Lifetime | 518 | US 283 | 96.70 |
| Finance and Banking | Lifetime | 761 | US 336 | 95.49 |
| Microbiology | Lifetime | 324 | US 150 | 94.50 |
| Applied Microbiology and Biotechnology | Lifetime | 152 | US 54 | 91.20 |
| Medical Biochemistry | Lifetime | 344 | US 108 | 90.85 |
| Endocrinology | Lifetime | 567 | US 235 | 84.15 |
| Critical Care and Intensive Care Medicine | Lifetime | 637 | US 274 | 74.84 |
| Accounting | 2021-2025 | 291 | US 127 | 91.83 |
| Financial Markets, Risk and Investment | 2021-2025 | 237 | US 84 | 89.26 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 24 | US 12 | 99.79 |
| Pneumonia and Respiratory Infections | Lifetime | 35 | US 17 | 99.77 |
| Antibiotic Resistance in Bacteria | Lifetime | 69 | US 26 | 99.71 |
| Bacterial Infections and Vaccines | Lifetime | 68 | US 33 | 99.24 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 100 | US 43 | 99.27 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 120 | US 63 | 99.34 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 105 | US 45 | 99.36 |
| Streptococcal Infections and Treatments | Lifetime | 140 | US 77 | 98.96 |
| Antibiotic Use and Resistance | Lifetime | 110 | US 47 | 99.19 |
| Blood transfusion and management | Lifetime | 61 | US 30 | 98.53 |
| Cancer therapeutics and mechanisms | Lifetime | 462 | US 246 | 97.59 |
| Credit Risk and Financial Regulations | Lifetime | 113 | US 58 | 97.16 |
| Mycobacterium research and diagnosis | Lifetime | 943 | US 306 | 96.16 |
| Blood donation and transfusion practices | Lifetime | 148 | US 69 | 96.51 |
| Blood groups and transfusion | Lifetime | 730 | US 329 | 96.04 |
| Financial Distress and Bankruptcy Prediction | Lifetime | 72 | US 17 | 95.86 |
| Veterinary medicine and infectious diseases | Lifetime | 276 | US 84 | 95.31 |
| Phenothiazines and Benzothiazines Synthesis and Activities | Lifetime | 564 | US 114 | 93.48 |
| Banking stability, regulation, efficiency | Lifetime | 941 | US 454 | 94.72 |
| Insurance and Financial Risk Management | Lifetime | 489 | US 203 | 93.71 |
| Blood disorders and treatments | Lifetime | 829 | US 322 | 92.32 |
| Nosocomial Infections in ICU | Lifetime | 842 | US 282 | 92.67 |
| Diphtheria, Corynebacterium, and Tetanus | Lifetime | 434 | US 146 | 86.32 |
| Infections and bacterial resistance | Lifetime | 361 | US 88 | 87.80 |
| Sustainable Development and Environmental Policy | Lifetime | 872 | US 201 | 74.87 |
| Environmental law and policy | Lifetime | 517 | US 160 | 73.86 |
| Environmental Philosophy and Ethics | Lifetime | 604 | US 191 | 60.15 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 216 | US 46 | 92.98 |
| Credit Risk and Financial Regulations | 2021-2025 | 54 | US 16 | 86.73 |
| Financial Distress and Bankruptcy Prediction | 2021-2025 | 83 | US 11 | 80.38 |
| Banking stability, regulation, efficiency | 2021-2025 | 512 | US 151 | 81.02 |